Page last updated: 2024-12-11

nitecapone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nitecapone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5464105
CHEMBL ID167055
CHEBI ID166596
SCHEMBL ID128420
MeSH IDM0160558

Synonyms (40)

Synonym
3-[(3,4-dihydroxy-5-nitrophenyl)methylidene]pentane-2,4-dione
CHEBI:166596
D03241
nitecapone (inn)
116313-94-1
nitecapone [inn]
or-462
nitecapona [inn-spanish]
or462
nitecapone
3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione
brn 6420063
2,4-pentanedione, 3-((3,4-dihydroxy-5-nitrophenyl)methylene)-
or 462
3-((3,4-dihydroxy-5-nitrophenyl)methylene)-2,4-pentanedione
nitecaponum [inn-latin]
3-(3,4-dihydroxy-5-nitrobenzylidiene)-2,4-pentanedione
CHEMBL167055 ,
3-(3,4-dihydroxy-5-nitro-benzylidene)-pentane-2,4-dione
bdbm50017848
nitecapona
98bs722498 ,
unii-98bs722498
nitecaponum
FT-0672738
3-[(3,4-dihydroxy-5-nitrophenyl)methylene]-2,4-pentanedione
SCHEMBL128420
3-(3,4-dihydroxy-5-nitrobenzylidene)pentane-2,4-dione
UPMRZALMHVUCIN-UHFFFAOYSA-N
AKOS024462971
DTXSID80151347
J-003423
2,4-pentanedione, 3-[(3,4-dihydroxy-5-nitrophenyl)methylene]-
3-(3,4-dihydroxy-5-nitrophenyl)methylene-2,4-pentanedione
Q7041230
A893586
EAO ,
MS-23746
HY-106842
CS-0026698

Research Excerpts

Overview

Nitecapone is an antioxidant molecule which has been shown to protect the heart against ischemia-reperfusion injury.

ExcerptReferenceRelevance
"Nitecapone is an antioxidant molecule which has been shown to protect the heart against ischemia-reperfusion injury. "( The effect of nitecapone on early graft function in experimental single lung transplantation.
Heikkilä, L; Hyytinen, TA; Mattila, SP; Rämö, J; Toivonen, HJ; Vainikka, T, 2000
)
2.11
"Nitecapone (OR-462) is a new selective COMT inhibitor with gastroprotective properties. "( COMT inhibition with nitecapone does not affect the tyramine pressor response.
Gordin, A; Sundberg, S, 1991
)
2.04

Effects

Nitecapone has been shown to have a protective effect against ischemia-reperfusion injury in experimental heart transplantation and in Langendorff preparations.

ExcerptReferenceRelevance
"Nitecapone has a beneficial effect on the preservation of the grafts in terms of functional recovery."( Nitecapone is of benefit to functional performance in experimental heart transplantation.
Holopainen, A; Mattila, SP; Nemlander, AT; Nissinen, E; Rämö, OJ; Vento, AE, 1997
)
2.46
"Nitecapone has a beneficial effect on the preservation of the grafts in terms of functional recovery."( Nitecapone is of benefit to functional performance in experimental heart transplantation.
Holopainen, A; Mattila, SP; Nemlander, AT; Nissinen, E; Rämö, OJ; Vento, AE, 1997
)
2.46
"Nitecapone (NC) has been shown to have beneficial effects on the functional recovery of rat hearts in Langendorff-preparation. "( Nitecapone inhibits myeloperoxidase in vitro and enhances functional performance after 8 h of ischemia in experimental heart transplantation.
Ahotupa, M; Holopainen, A; Mattila, SP; Nemlander, AT; Nissinen, E; Rämö, OJ; Vento, AE, 1999
)
3.19
"Nitecapone has been shown to have a protective effect against ischemia-reperfusion injury in experimental heart transplantation and in Langendorff preparations. "( Nitecapone as an additive to crystalloid cardioplegia in patients who had coronary artery bypass grafting.
Aittomäki, J; Heikkilä, LJ; Rämö, OJ; Salo, JA; Sipponen, J; Vento, AE; Verkkala, KA, 1999
)
3.19

Treatment

Both nitecapone treatments significantly reduced mechanical allodynia and withdrawal thresholds were 80-95% higher compared with the control group. In niteCapone treated hearts the content of oxidized proteins and lipids (carbonyl groups and endogenous lipid fluorescent products) decreased.

ExcerptReferenceRelevance
"Both nitecapone treatments significantly reduced mechanical allodynia and withdrawal thresholds were 80-95% higher compared with the control group."( Nitecapone reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats.
Käenmäki, M; Kalso, EA; Kambur, O; Kontinen, VK; Männistö, PT; Pusa, AM, 2011
)
2.27
"In nitecapone treated hearts the content of oxidized proteins and lipids (carbonyl groups and endogenous lipid fluorescent products) decreased."( Nitecapone protects the Langendorff perfused heart against ischemia-reperfusion injury.
Catudioc, J; Khwaja, S; Packer, L; Serbinova, E; Valenza, M, 1993
)
2.24
"Nitecapone-treated diabetic rats were protected from these intracellular modifications."( Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats.
Aperia, A; Cheng, SX; DiBona, GF; Eklöf, AC; Jaremko, G; Körner, A; Lal, MA; Matsuo, Y; Zelenin, S, 2000
)
1.03
"Nitecapone treatment increased the plasma free radical trapping capacity threefold."( The effect of nitecapone on early graft function in experimental single lung transplantation.
Heikkilä, L; Hyytinen, TA; Mattila, SP; Rämö, J; Toivonen, HJ; Vainikka, T, 2000
)
1.39
"Pretreatment with nitecapone (30 mg/kg i.p.), a COMT inhibitor, or selegiline (10 mg/kg i.p.), a MAO-B inhibitor potentiated the motor stimulant actions of subthreshold doses of the L-DOPA (100 mg/kg i.p.) and carbidopa (10 mg/kg i.p.) combination."( Nitecapone and selegiline as effective adjuncts to L-DOPA in reserpine-induced catatonia in mice.
Kulkarni, SK; Singh, A,
)
1.9

Toxicity

ExcerptReferenceRelevance
" LD50 values of three of these compounds were assessed after intraperitoneal administration with a special emphasis on interactions with drugs increasing catecholaminergic neurotransmission."( Acute toxicity of three new selective COMT inhibitors in mice with special emphasis on interactions with drugs increasing catecholaminergic neurotransmission.
Männistö, PT; Törnwall, M, 1991
)
0.28

Bioavailability

ExcerptReferenceRelevance
" Nitecapone slightly but significantly increased the relative bioavailability of L-Dopa."( Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers.
Gordin, A; Järvinen, M; Kaakkola, S; Nissinen, E; Pentikäinen, PJ; Rita, H; Schultz, E; Wikberg, T, 1990
)
1.43
" In animal studies, these compounds inhibit effectively the O-methylation of L-dopa, thus improving its bioavailability and brain penetration and potentiating its behavioural effects."( General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
Gordin, A; Kaakkola, S; Männistö, PT, 1994
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Nitecapone (10-100 mg/kg orally) induced at 1 h after dosing a significant and dose-dependent increase in gastric mucosal prostaglandin E2 release."( Role of gastric mucosal eicosanoid production in the cytoprotection induced by nitecapone.
Aho, PA; Lindén, IB, 1992
)
1.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydroxycinnamic acidAny member of the class of cinnamic acids carrying one or more hydroxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
dopamine degradation431

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Catechol O-methyltransferaseRattus norvegicus (Norway rat)IC50 (µMol)0.01800.00222.81277.0795AID49921
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID157596Inhibitory activity against Phenol sulfotransferase1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors.
AID191330Compound was tested for acute oral toxicity in Wistar rats1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors.
AID188140Inhibition of formation of 3OMD in rat serum by 80 %, when compound was administered in combination with L-Dopa and carbidopa1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors.
AID49921In vitro inhibitory activity against catechol O-methyltransferase of rat brain using 3,4-dihydroxybenzoic acid as the substrate.1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (63)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (6.35)18.7374
1990's50 (79.37)18.2507
2000's6 (9.52)29.6817
2010's2 (3.17)24.3611
2020's1 (1.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.97 (24.57)
Research Supply Index4.30 (2.92)
Research Growth Index5.63 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (5.80%)5.53%
Reviews2 (2.90%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other63 (91.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]